|
1
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murray CJ and Lopez AD: Alternative
projections of mortality and disability by cause 1990–2020: Global
burden of disease study. Lancet. 349:1498–1504. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lam WK, White NW and Chan-Yeung MM: Lung
cancer epidemiology and risk factors in Asia and Africa. Int J
Tuberc Lung Dis. 8:1045–1057. 2004.PubMed/NCBI
|
|
4
|
Rezazadeh A, Laber DA, Ghim SJ, Jenson AB
and Kloecker G: The role of human papilloma virus in lung cancer: A
review of the evidence. Am J Med Sci. 338:64–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Castle PE, Cuzick J, Stoler MH, Wright TC
Jr, Reid JL, Dockter J, Giachetti C and Getman D: Detection of
human papillomavirus 16, 18, and 45 in women with ASC-US cytology
and the risk of cervical precancer: Results from the CLEAR HPV
study. Am J Clin Pathol. 143:160–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slama J, Sehnal B, Dusek L, Zima T and
Cibula D: Impact of risk factors on prevalance of anal HPV
infection in women with simultaneous cervical lesion. Neoplasma.
62:308–314. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zur Hausen H: Papillomaviruses in the
causation of human cancers-a brief historical account. Virology.
384:260–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park MS, Chang YS, Shin JH, Kim DJ, Chung
KY, Shin DH, Moon JW, Kang SM, Hahn CH, Kim YS, et al: The
prevalence of human papillomavirus infection in Korean non-small
cell lung cancer patients. Yonsei Med J. 48:69–77. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Isa SI, Kurahara Y, Yamamoto S, Tamiya A,
Omachi N, Asami K, Okishio K, Utsumi T, Ito N, Yoon HE, et al:
Molecular analysis of human papillomavirus in never-smokers with
non-small cell lung cancer. Oncol Lett. 9:927–929. 2015.PubMed/NCBI
|
|
10
|
Ragin C, Obikoya-Malomo M, Kim S, Chen Z,
Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso
NE, et al: HPV-associated lung cancers: An international pooled
analysis. Carcinogenesis. 35:1267–1275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng YW, Chiou HL, Sheu GT, Hsieh LL,
Chen JT, Chen CY, Su JM and Lee H: The association of human
papillomavirus 16/18 infection with lung cancer among nonsmoking
Taiwanese women. Cancer Res. 61:2799–2803. 2001.PubMed/NCBI
|
|
12
|
Srinivasan M, Taioli E and Ragin CC: Human
papillomavirus type 16 and 18 in primary lung cancers-a
meta-analysis. Carcinogenesis. 30:1722–1728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koshiol J, Rotunno M, Gillison ML, Van
Doorn LJ, Chaturvedi AK, Tarantini L, Song H, Quint WG, Struijk L,
Goldstein AM, et al: Assessment of human papillomavirus in lung
tumor tissue. J Natl Cancer Inst. 103:501–507. 2001. View Article : Google Scholar
|
|
14
|
Proctor I, Stoeber K and Williams GH:
Biomarkers in bladder cancer. Histopathology. 57:1–13. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Helt AM, Funk JO and Galloway DA:
Inactivation of both the retinoblastoma tumor suppressor and p21 by
the human papillomavirus type 16 E7 oncoprotein is necessary to
inhibit cell cycle arrest in human epithelial cells. J Virol.
76:10559–10568. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murao K, Yoshioka R and Kubo Y: Human
papillomavirus infection in Bowen disease: Negative p53 expression,
not p16INK 4a overexpression, is correlated with human
papillomavirus- associated Bowen disease. J Dermatol. 41:878–884.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vainshtein J, McHugh JB, Spector ME,
Walline HM, Komarck CM, Stenmark MH, Prince ME, Worden FP, Wolf GT,
Bradford CR, et al: Human papillomavirus-related oropharyngeal
cancer: HPV and p16 status in the recurrent versus parent tumor.
Head Neck. 37:8–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maniakas A, Moubayed SP, Ayad T, Guertin
L, Nguyen-Tan PF, Gologan O, Soulieres D and Christopoulos A:
North-American survey on HPV-DNA and p16 testing for head and neck
squamous cell carcinoma. Oral Oncol. 50:942–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Umbreit C, Aderhold C, Faber A, Sauter A,
Hofheinz RD, Stern-Straeter J, Hoermann K and Schultz JD:
Imatinib-associated matrix metalloproteinase suppression in
p16-positive squamous cell carcinoma compared to HPV-negative HNSCC
cells in vitro. Oncol Rep. 32:668–676. 2014.PubMed/NCBI
|
|
20
|
Zhang EY and Tang XD: Human papillomavirus
type 16/18 oncoproteins: Potential therapeutic targets in
non-smoking associated lung cancer. Asian Pac J Cancer Prev.
13:5363–5369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suzuki Y, Oonishi T, Kudo T and Doi H:
LKB1, TP16, EGFR and KRAS somatic mutations in lung adenocarcinomas
from a Chiba Prefecture, Japan cohort. Drug Discov Ther. 6:24–30.
2012.PubMed/NCBI
|
|
22
|
Trbusek M, Smardova J, Malcikova J,
Sebejova L, Dobes P, Svitakova M, Vranova V, Mraz M, Francova HS,
Doubek M, et al: Missense mutations located in structural p53
DNA-binding motifs are associated with extremely poor survival in
chronic lymphocytic leukemia. J Clin Oncol. 29:2703–2708. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vainshtein J, McHugh JB, Spector ME,
Walline HM, Komarck CM, Stenmark MH, Prince ME, Worden FP, Wolf GT,
Bradford CR, et al: Human papillomavirus-related oropharyngeal
cancer: HPV and p16 status in the recurrent versus parent tumor.
Head Neck. 37:8–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S: Metastatic non-small-cell lung cancer
(NSCLC): ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 25(Suppl 3): iii27–iii39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Syrjanen KJ: Condylomatous changes in
neoplastic bronchial epithelium. Respiration. 38:299–304. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hasegawa Y, Ando M, Kubo A, Isa S,
Yamamoto S, Tsujino K, Kurata T, Ou SH, Takada M and Kawaguchi T:
Human papilloma virus in non-small cell lung cancer in never
smokers: A systematic review of the literature. Lung Cancer.
83:8–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gillison ML, Koch WM, Capone RB, Spafford
M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, et
al: Evidence for acausal association between human papillomavirus
and a subset of head and neck cancers. J Natl Cancer Inst.
92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kreimer AR, Clifford GM, Boyle P and
Franceschi S: Human papillomavirus types in head and neck squamous
cell carcinomas worldwide: A systematic review. Cancer Epidemiol
Biomarkers Prey. 14:467–475. 2005. View Article : Google Scholar
|
|
29
|
Subramanian J and Govindan R: Molecular
genetics of lung cancer in people who have never smoked. Lancet
Oncol. 9:676–682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Molina-Vila MA, Bertran-Alamillo J, Gascó
A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L,
Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, et al:
Nondisruptive p53 mutations are associated with shorter survival in
patients with advanced non-small cell lung cancer. Clin Cancer Res.
20:4647–4659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gatta LB, Balzarini P, Tironi P, Berenzi
A, Benetti A, Angiero F, Grigolato P and Dessy E: Human
papillomavirus DNA and p16 gene in squamous cell lung carcinoma.
Anticancer Res. 32:3085–3089. 2012.PubMed/NCBI
|
|
32
|
Su CY, Chang YC, Chan YC, Lin TC, Huang
MS, Yang CJ and Hsiao M: MTAP is an independent prognosis marker
and the concordant loss of MTAP and p16 expression predicts short
survival in non-small cell lung cancer patients. Eur J Surg Oncol.
40:1143–1150. 2014. View Article : Google Scholar : PubMed/NCBI
|
